伊托必利与莫沙必利比较治疗功能性消化不良的系统评价

System Evaluation of Itopride and Mosapridein in the Treatment of Functional Dyspepsia

目的：评价对比伊托必利与莫沙必利治疗功能性消化不良（FD）的疗效与安全性。方法2015年1月～2015年6月，筛选150例FD患者，据入院顺序，将患者随机分为伊托必利组、莫沙必利组各75例，伊托必利组给予伊托必利治疗，50 mg/d，莫沙必利组给予莫沙必利治疗，5 mg/d。结果伊托必利组退出1例、莫沙必利组退出5例；伊托必利组痊愈率、显效率、有效率、无效率与莫沙必利组比较，差异无统计意义（u=0.10，P=0.919＞0.05）；伊托必利组3个月内复发或加重发生率22..97%（17/74）、莫沙必利组复发或加重发生率22.85%（16/70），差异无统计学意义（χ2=0.03，P=0.856＞0.05）。两组均未见不良反应。结论伊托必利与莫沙必利治疗FD在症状改善、总体疗效、复发、不良反应方面无显著性差异，可选择更经济的药物。

Objective Compared with the efficacy and safety of single use of itopride or mosapride in the treatment of functional dyspepsia （FD）. Methods From January 2015 to June 2015, 150 cases of FD patients were randomly divided into itopride group and mosapride group, according to the order of admission, 75 cases in each group.Itopride group was treated with itopride, 50mg/d, mosapride group was treated with mosapride, 5mg/d.Results 1 case backed out Itopride group, 1 case backed out mosapride group; itopride group, There were no statistically significant difference about the cure rate, the markedly effective rate, the effective rate and the ineffective rate between mosapride group and itopride group （u=0.10,P=0.919＆gt;0.05）; The rate of recurrence or exacerbation of itopride group within 3 months was 22.97%, that of mosapride group was 22.85%, adverse reaction rate of two groups was 0.0%, the difference was not statistically signiifcant （ χ2=0.03,P=0.856＆gt;0.05）. Conclusion There was no statistically significant difference with the improvement of symptoms, the overall curative effect, the rate of recurrence andthe rate of adverse reaction with application of Itopride and mosapride in the treatment of FD, it is sensible to choose more economical drugs.